FGFR1 and lung carcinoma: To identify novel biomarkers for evaluating the therapeutic response to FGFRi, TMT-labeled mass spectrometry-based proteomics was carried out in a FGFRi-sensitive cell line (NCI-H1581, a lung cancer cell line with FGFR1 amplification) upon AZD4547 treatment (Figure 1A).